Retatrutide Lawsuit: Drug or Biologic? The FDA Decision and Lilly's Appeal

The retatrutide lawsuit that matters for approval is Lilly's own case against the FDA, and it's about a label. On October 2, 2026 the FDA decided, for the second time, that retatrutide is a drug and not a biological product. That points Lilly to a new drug application (NDA) instead of the Biologics License Application (BLA) it had planned, unless its appeal changes the answer. When we checked the Seventh Circuit docket on October 31, 2026, the last filings were dated October 8 and there was no ruling. Lilly's separate suits against online sellers are at the end of this page.

Lilly last said, on September 29, 2026, that it planned to submit retatrutide in the first quarter of 2027 as a BLA. The FDA's October 2 letter says an application would instead go under section 505 of the Federal Food, Drug, and Cosmetic Act. Overall approval status lives on is retatrutide FDA approved, and launch timing on retatrutide release date.

What the retatrutide lawsuit is about

US law has two main routes for a new medicine. A drug goes through section 505 of the Federal Food, Drug, and Cosmetic Act with an NDA; a biological product goes through section 351 of the Public Health Service Act with a BLA. The company doesn't get to pick. It depends on what the molecule is.

The Public Health Service Act lists what counts as a biological product, and "protein" is on the list, along with any "analogous product" (42 U.S.C. 262(i)). Since a December 2019 change in the law, that includes proteins made by chemical synthesis, according to the FDA's October 2 letter. Congress never defined protein, so the FDA did, in a rule that took effect in March 2020: "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size."

Retatrutide sits right on that line. The FDA's letter describes it as a chain of 39 alpha amino acids with a side chain attached at position 17: a small linker called ADO, one gamma glutamate, and a C20 fatty diacid that Lilly Medical Information says lets it bind albumin and prolongs its half-life. Lilly counts the ADO and the glutamate as amino acids and gets 41. The FDA counts only alpha amino acids that sit in a chain and gets 39. The case turns on two small pieces of a side chain. Our retatrutide structure page walks through the molecule.

Why drug or biologic matters

Either way, the government's brief says, Lilly's product "will be subject to a detailed FDA review process." The differences show up after approval, in how long retatrutide is shielded from cheaper copies and in how the price can be pushed down later. Here's the side-by-side, from the statutes and FDA documents.

Count from approval day, whenever it comes. As a drug, nobody could even submit a generic application until year 5 (year 4 with a patent challenge). As a biologic, a biosimilar could be filed in year 4 but not approved before year 12. Patents are a separate layer that can outlast both, per the FDA's exclusivity FAQ; we haven't checked which retatrutide patents exist.

The parties describe the stakes differently. The government's brief says biologics "generally benefit from a substantially longer exclusivity period before follow-on products can enter the market." The Outsourcing Facilities Association, a trade group for compounding outsourcing facilities that filed a brief backing the FDA, lists 5 advantages it says Lilly would gain, starting with longer exclusivity and limits on compounding. Lilly's opening brief frames it as process: drugs and biologics "may involve different application processes and product labeling," and a sponsor "must know well in advance which regulatory regime will govern its application."

What Lilly argues

From its April 1, 2026 brief and its October 8 supplemental brief, Lilly makes three points.

1. Lilly says retatrutide is a protein under the FDA's own words. The rule says size is "based on the total number of amino acids," and the word "alpha" appears in "alpha amino acid polymer" but not in the size requirement. Count every amino acid and you get 41, which is "greater than 40."
2. Lilly says the FDA ran out of time. By statute, the FDA has 60 days to answer a request to classify a product, and if it doesn't, the company's recommendation "shall be considered to be a final determination" (21 U.S.C. 360bbb-2). Lilly argues that once the district court vacated the FDA's answer, no valid decision existed, so its biologic recommendation took effect by law instead of the FDA getting a do-over.
3. Lilly says only the appeals court can fix it. In October, Lilly told the court it "plans to file its application for retatrutide's approval no later than the first quarter of 2027" and needs to know which pathway to use. Sending the case back, it wrote, "could force Lilly to choose between having retatrutide submitted when it is ready for patients and having it classified correctly." It also says the FDA took "nearly ten months" to decide on remand and then announced "a nearly identical bright-line rule."

What the FDA argues

The FDA's answer starts with chemistry. Only alpha amino acids link to each other by peptide bonds into a protein's backbone, which is why its letter calls them the "building blocks of proteins." ADO is an amino acid by the textbook definition, but its amino and acid groups sit 5 carbons and 2 oxygens apart, so it isn't an alpha amino acid. The FDA assumed, without deciding, that the gamma glutamate is an alpha amino acid, but ADO and the glutamate together don't form a chain of alpha amino acids. Even if it were counted, the letter says, the total "would only total 40."

On the question the district court sent back, the FDA now says anything "analogous" to a protein needs two features at minimum: chains totaling more than 40 alpha amino acids, and a specific, defined sequence. Retatrutide has the second (a specific, defined 39-link chain) but not the first. So, verbatim, it "is neither a 'protein' nor an 'analogous product' to a 'protein' and is therefore not a biological product."

The letter also points at Lilly's own tirzepatide. It has the same design, a 39 alpha amino acid chain with "two ADO residues and one gamma-glutamate residue," and it was approved as a drug under new drug applications as Mounjaro and Zepbound. Lilly's labeling dated July 28, 2023 called it "a 39-amino-acid ... peptide," the FDA notes.

On the 60-day rule, the FDA says it answered Lilly's January 19, 2024 request on March 18, 2024, "within the 60-day window," and that the statute "simply does not address" an answer a court later vacates. And on jurisdiction, the Justice Department's October 8 letter argues that "Lilly cannot appeal a district court's order remanding to an agency." It asks the court to revisit its own 2008 precedent that allows such appeals, while accepting that under that precedent the court could hear the protein question.

Timeline of the dispute, request to appeal

When will the appeals court rule?

Nobody knows, and nothing on the docket sets a date. The panel's first question isn't the amino acid count. It's whether it can hear the appeal at all, which is what its September 24 order asked both sides to brief.

The parties describe two paths. If the court decides it lacks jurisdiction, the Justice Department says Lilly can challenge the FDA's October 2 decision in district court and appeal once, at the end. Lilly says that would mean a brand-new lawsuit, and that it couldn't re-raise its protein and 60-day arguments there because the district court has already rejected them. If the court takes the case, it decides those two questions, and Lilly is asking for an order that the FDA treat its biologic request as granted.

We found no new Lilly suit against the October 2 decision in the CourtListener RECAP archive on October 31, 2026. The archive holds only what someone has uploaded, so read that as "none found," not "none filed."

Does the FDA decision delay retatrutide approval?

On its own, no. The trial results Lilly submits don't change with the label, and Lilly's own request asked for the same FDA center, the Center for Drug Evaluation and Research, to handle it as a BLA. The user fee goals match too: act on 90% of standard new-molecule NDAs and original BLAs within 10 months of the 60-day filing check. The retatrutide release date page turns those goals into calendar dates.

The risk to timing is the one Lilly named itself: having to choose between filing when retatrutide is ready and waiting for the classification fight to end. Lilly hasn't said publicly which it will do. Its October 28, 2026 trial release and October 29 quarterly report give no submission timing and don't mention a BLA or NDA.

Some things don't move at all. Retatrutide is still investigational, and the FDA says it "cannot be used in compounding under federal law" today. A court win for Lilly wouldn't make an online vial legal or make it Lilly's product. If you're weighing retatrutide for sale listings anyway, that page covers batch test reports and the red flags worth walking away over.

Our read: for someone waiting on a prescription, this case is mostly about years 4 through 12 after approval, when cheaper copies and Medicare negotiation could arrive, not about the approval date itself. The near-term date still rides on when Lilly files.

Lilly's lawsuits against sellers

These are separate cases, and none decides drug or biologic. On August 12, 2026, Lilly announced 6 lawsuits against US sellers of retatrutide. The CourtListener RECAP archive also lists 5 more complaints Lilly filed on October 8, 2026 in federal court; we haven't summarized them here.

In one August case, the seller moved to dismiss on October 2, 2026, arguing that Lilly lacks standing because Lilly doesn't sell retatrutide itself; we found no ruling on that motion. What these suits mean for buyers is on is retatrutide legal, and Lilly's public statements are collected on Eli Lilly and retatrutide.

To follow the main case yourself, the Seventh Circuit docket for No. 26-1301 is free to read on CourtListener; a ruling or a dismissal would appear there.